I

Immunovant Tech Stack

Clinical-stage anti-FcRn immunology company developing targeted autoimmune therapies

Biotechnology Research New York 201–500 employees Founded 2018 Public Company

Immunovant is a public, clinical-stage biotech focused on anti-FcRn monoclonal antibody therapies for autoimmune disease. The hiring mix—skewed toward manufacturing, operations, and regulatory roles at director+ level—combined with active projects in formulation stability, CGMP scale-up, and global regulatory filings, signals a company transitioning from research into late-stage development and manufacturing readiness. Pain-point density around regulatory gaps, compliance, and technology transfer underscores the operational complexity of moving a therapeutic candidate toward market approval.

Tech Stack 14 technologies

Core StackActive Directory Okta Intune WinNonlin NONMEM Monolix R Azure Entra ID Microsoft 365 Windows 11 iPadOS SharePoint PowerShell macOS

What Immunovant Is Building

◆Challenges

Remediating regulatory gaps
Maintaining compliance
Process scale up
Technology transfer
Regulatory filing
Expediting development
Mitigating regulatory risks
Meeting submission deadlines
Device refreshes
Os upgrades

▲Active Projects

Stable formulations of monoclonal antibodies for subcutaneous administration via pre-filled syringe and vials
Technical transfer protocols for cgmp drug product manufacturing facilities
Due diligence on potential partners for fit synergies
Quality systems improvement
Risk-based methodology implementation
Process scale up
Technology transfer
Regulatory filing
Global cmc regulatory filings
Policy development for gxps

Hiring Activity

Accelerating9 roles · 4 in 30d

Department

Manufacturing

2

Ops

2

Healthcare

1

Marketing

1

Regulatory

1

Research

1

Support

1

Seniority

Director

6

Senior

3

Company intelligence

Find more companies like Immunovant by tech stack, pain points and active projects

Get started free

About Immunovant

Immunovant develops targeted immunology therapies using anti-FcRn technology to treat autoimmune diseases. Founded in 2018 and publicly listed, the company operates from New York with a team of 201–500 employees. Current work centers on formulating stable monoclonal antibodies for subcutaneous delivery (pre-filled syringes and vials), establishing CGMP manufacturing protocols, and advancing global regulatory submissions. The organization is actively hiring across manufacturing, regulatory affairs, and operations, primarily in the United States and Canada, reflecting the resource intensity of clinical-stage drug development and anticipated scale-up activities.

HeadquartersNew York

Company Size201–500 employees

Founded2018

Hiring MarketsUnited States, Canada

Frequently Asked Questions

What is Immunovant's core drug candidate focused on?

Immunovant develops anti-FcRn monoclonal antibody therapies designed for stable subcutaneous administration via pre-filled syringe and vials, targeting autoimmune diseases with targeted mechanisms.

What is Immunovant's main challenge right now?

Regulatory compliance and technology transfer are top priorities. Active pain points include remediating regulatory gaps, process scale-up, maintaining compliance, and meeting regulatory filing deadlines as the company advances toward market submissions.